PharmVar GeneFocus: CYP2C9.
Katrin Sangkuhl, Karla Claudio-Campos, Larisa H Cavallari, Jose A G Agundez, Michelle Whirl-Carrillo, Jorge Duconge, Andria L Del Tredici, Mia Wadelius, Mariana Rodrigues Botton, Erica L Woodahl, Stuart A Scott, Teri E Klein, Victoria M Pratt, Ann K Daly, Andrea Gaedigk
Clinical pharmacology and therapeutics 2021 SepThe Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs, including nonsteroidal anti-inflammatory drugs, phenytoin, antidiabetic agents, and angiotensin receptor blockers. Variable CYP2C9 activity is of particular importance regarding efficacy and safety of warfarin and siponimod as indicated in their package inserts. This GeneFocus provides a comprehensive overview and summary of CYP2C9 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium. © 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.
Citation
Katrin Sangkuhl, Karla Claudio-Campos, Larisa H Cavallari, Jose A G Agundez, Michelle Whirl-Carrillo, Jorge Duconge, Andria L Del Tredici, Mia Wadelius, Mariana Rodrigues Botton, Erica L Woodahl, Stuart A Scott, Teri E Klein, Victoria M Pratt, Ann K Daly, Andrea Gaedigk. PharmVar GeneFocus: CYP2C9. Clinical pharmacology and therapeutics. 2021 Sep;110(3):662-676
Mesh Tags
Substances
PMID: 34109627
View Full Text
